tbuckley/cabot-search huggingface dataset:
Time to Focus on Value-Based Metrics for Cancer Care?
Authors: Jill R. Dietz, Peter Pronovost
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A Multicenter Comparison of Rates of Central Venous Catheter-Associated Bloodstream Infections By Central Venous Catheter Type Among Pediatric Patients Receiving Treatment for Newly Diagnosed Acute Myeloid Leukemia
Authors: Joseph P. Horowitz, Brian T Fisher, Julia E Szymczack, Yimei Li, Julianna P Mann, Tyler Galvelis, Richard Suarez, Leah Sack, Christy He, Hugues Yver, Andria Stevens, Staci D. Arnold, M. Monica Monica Gramatges, Naomi Winick, Nobuko Hijiya, Jennifer C. Yu, Amir Mian, Elizabeth A. Raetz, Rajen Mody, Meret Henry, Anderson Collier, Craig Lotterman, Richard Aplenc, Kelly D Getz
Journal: Blood (2017)
Abstract P273: Treatment Patterns Among Vorapaxar New Users in a US Outpatient Clinical Setting
Authors: Cathy Anne Pinto, Eileen Fonseca, Gregory P. Hess, Massimiliano Alfonzo Manzi, John Acquavella
Journal: Circulation (2018)

Introduction: Vorapaxar is a once daily oral protease-activated receptor-1 (PAR-1) antagonist for the reduction of thrombotic events in patients with a history of myocardial infarction or peripheral arterial disease. Efficacy and safety was evaluated in a large randomized clinical trial (TRA 2°P TIMI 50), with a median follow-up of 30 months. This is the first descriptive study of vorapaxar treatment patterns in routine clinical practice. Objectives: To evaluate medication adherence and persistence among vorapaxar new users. Methods: Vorapaxar new users ≥18 years of age were identified with an index prescription date between June 2014 and October 2015 with ≥1 years of follow-up through October 2016. The qualifying prescription was identified from Symphony Health’s US outpatient pharmacy claims linked to private practitioner claims and hospital data. Baseline characteristics were assessed using a 1-year look-back prior to the index prescription date. Adherence was defined as a medication possession ratio (MPR) ≥80%, and persistence was defined allowing for up to a 7-day gap in days supply. Sensitivity analysis with 15-day gap to define persistence was performed. Results: The 529 vorapaxar new users included in the analysis were predominantly male (67%), 11% African American and 70% Caucasian, and had a mean (SD) age of 65.2 (10.5) years. At the end of 3, 6, and 12 months, 61%, 45%, and 32%, respectively, of new users were adherent on vorapaxar. A majority (68%) of vorapaxar users were persistent at 3 months, 48% at 6 months, and 29% at 12 months. An additional 10% restarted therapy by the end of the first year after a period of supply interruption. Results of the sensitivity analysis for persistence using 15-day allowable gap were within 1-2% of primary analysis. The median (IQR) time to discontinuation of therapy during the first year was 2.6 (1.2-6.1) months. During the first year, a median (IQR) of 5 (3-9) prescriptions per patient were filled- majority 30 day fills. Conclusions: Medication adherence and persistence of use decreased over time. One-third of patients were adherent and/or persistent at one year. Further research is warranted to understand treatment pattern differences by indication of use and factors affecting adherence and discontinuation.
Transcriptional frameshifts contribute to protein allergenicity
Authors: Benoit Thouvenot, Olivier Roitel, Julie Tomasina, Benoit Hilselberger, Christelle Richard, Sandrine Jacquenet, Françoise Codreanu-Morel, Martine Morisset, Gisèle Kanny, Etienne Beaudouin, Christine Delebarre-Sauvage, Thierry Olivry, Claude Favrot, Bernard E. Bihain
Journal: Journal of Clinical Investigation (2020)

Transcription infidelity (TI) is a mechanism that increases RNA and protein diversity. We found that single-base omissions (i.e., gaps) occurred at significantly higher rates in the RNA of highly allergenic legumes. Transcripts from peanut, soybean, sesame, and mite allergens contained a higher density of gaps than those of nonallergens. Allergen transcripts translate into proteins with a cationic carboxy terminus depleted in hydrophobic residues. In mice, recombinant TI variants of the peanut allergen Ara h 2, but not the canonical allergen itself, induced, without adjuvant, the production of anaphylactogenic specific IgE (sIgE), binding to linear epitopes on both canonical and TI segments of the TI variants. The removal of cationic proteins from bovine lactoserum markedly reduced its capacity to induce sIgE. In peanut-allergic children, the sIgE reactivity was directed toward both canonical and TI segments of Ara h 2 variants. We discovered 2 peanut allergens, which we believe to be previously unreported, because of their RNA-DNA divergence gap patterns and TI peptide amino acid composition. Finally, we showed that the sIgE of children with IgE-negative milk allergy targeted cationic proteins in lactoserum. We propose that it is not the canonical allergens, but their TI variants, that initiate sIgE isotype switching, while both canonical and TI variants elicit clinical allergic reactions.
Requisite Skills and the Meaningful Measurement of Cognition
Authors: Richard S. E. Keefe, Michael F. Green, Philip D. Harvey
Journal: JAMA Psychiatry (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Metagenome Data on Intestinal Phage-Bacteria Associations Aids the Development of Phage Therapy against Pathobionts
Authors: Kosuke Fujimoto, Yasumasa Kimura, Masaki Shimohigoshi, Takeshi Satoh, Shintaro Sato, Georg Tremmel, Miho Uematsu, Yunosuke Kawaguchi, Yuki Usui, Yoshiko Nakano, Tetsuya Hayashi, Koji Kashima, Yoshikazu Yuki, Kiyoshi Yamaguchi, Yoichi Furukawa, Masanori Kakuta, Yutaka Akiyama, Rui Yamaguchi, Sheila E. Crowe, Peter B. Ernst, Satoru Miyano, Hiroshi Kiyono, Seiya Imoto, Satoshi Uematsu
Journal: Cell Host & Microbe (2020)
Prognostic Variation Among Very High-Risk and High-Risk Individuals With Atherosclerotic Cardiovascular Disease
Authors: Yejin Mok, Shoshana H. Ballew, Richard Brandon Stacey, Joseph Rossi, Silvia Koton, Anna M. Kucharska-Newton, Patricia P. Chang, Josef Coresh, Wayne Rosamond, Kunihiro Matsushita
Journal: Journal of the American College of Cardiology (2020)
LBA-6 Safety, feasibility, tolerability, and preliminary efficacy of perioperative systemic therapy for resectable colorectal peritoneal metastases: Pilot phase of a randomised trial (CAIRO6)
Authors: K. Rovers, C. Bakkers, S. Nienhuijs, J. Burger, G. Creemers, A. Brandt-Kerkhof, J. Tuynman, A. Aalbers, M. Wiezer, P. de Reuver, P. Hemmer, W. van Grevenstein, I. van 't Erve, P. Snaebjornsson, J. Nederend, M. Lahaye, M. Dijkgraaf, C. Punt, P. Tanis, I. de Hingh
Journal: Annals of Oncology (2020)
Author Correction: Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation
Authors: Andrew S. Mendiola, Jae Kyu Ryu, Sophia Bardehle, Anke Meyer-Franke, Kenny Kean-Hooi Ang, Chris Wilson, Kim M. Baeten, Kristina Hanspers, Mario Merlini, Sean Thomas, Mark A. Petersen, Alexander Williams, Reuben Thomas, Victoria A. Rafalski, Rosa Meza-Acevedo, Reshmi Tognatta, Zhaoqi Yan, Samuel J. Pfaff, Michael R. Machado, Catherine Bedard, Pamela E. Rios Coronado, Xiqian Jiang, Jin Wang, Michael A. Pleiss, Ari J. Green, Scott S. Zamvil, Alexander R. Pico, Benoit G. Bruneau, Michelle R. Arkin, Katerina Akassoglou
Journal: Nature Immunology (2020)
Abstract 10324: Close Association Between Circulating High-sensitivity Cardiac Troponin I and Presence Of Metabolic Syndrome in the General Population
Authors: Tomonori Sugiura, Yasuaki Dohi, Hiroyuki Takase, Sumiyo Yamashita, Tatsuya Mizoguchi, Yoshihiro Seo, Satoshi Fujii, Nobuyuki Ohte
Journal: Circulation (2019)

Introduction: Individuals with metabolic syndrome reportedly have an increased risk of cardiovascular disease, although the association between asymptomatic myocardial damage and metabolic syndrome...
P-260 Naïve indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy versus standard-of-care treatment in unresectable locally advanced pancreatic cancer
Authors: S. Allerdice, N. Wilson, D. Turner, P. McCloud, D. Kenny, A. Cowley, C. Taylor
Journal: Annals of Oncology (2020)
P-279 Clinical utility of circulating tumor DNA in resectable and advanced pancreatic cancer
Authors: A. Popova, M. Fedyanin, I. Pokataev, D. Shamovskaya, N. Kudashkin, U. Boyarskikh, A. Kechin, I. Oscorbin, E. Moroz, A. Trigolosov, M. Filipenko, D. Podluzhnyi, S. Tjulandin
Journal: Annals of Oncology (2020)
Effectiveness of Sequential Psychological and Medication Therapies for Insomnia Disorder
Authors: Charles M. Morin, Jack D. Edinger, Simon Beaulieu-Bonneau, Hans Ivers, Andrew D. Krystal, Bernard Guay, Lynda Bélanger, Ann Cartwright, Bryan Simmons, Manon Lamy, Mindy Busby
Journal: JAMA Psychiatry (2020)

Despite evidence of efficacious psychological and pharmacologic therapies for insomnia, there is little information about what first-line treatment should be and how best to proceed when initial treatment fails.To evaluate the comparative efficacy of 4 treatment sequences involving psychological and medication therapies for insomnia and examine the moderating effect of psychiatric disorders on insomnia outcomes.In a sequential multiple-assignment randomized trial, patients were assigned to first-stage therapy involving either behavioral therapy (BT; n = 104) or zolpidem (zolpidem; n = 107), and patients who did not remit received a second treatment involving either medication (zolpidem or trazodone) or psychological therapy (BT or cognitive therapy [CT]). The study took place at Institut Universitaire en Santé Mentale de Québec, Université Laval, Québec City, Québec, Canada, and at National Jewish Health, Denver, Colorado, and enrollment of patients took place from August 2012 through July 2017.The primary end points were the treatment response and remission rates, defined by the Insomnia Severity Index total score.Patients included 211 adults (132 women; mean [SD] age, 45.6 [14.9] years) with a chronic insomnia disorder, including 74 patients with a comorbid anxiety or mood disorder. First-stage therapy with BT or zolpidem produced equivalent weighted percentages of responders (BT, 45.5%; zolpidem, 49.7%; OR, 1.18; 95% CI, 0.60-2.33) and remitters (BT, 38.03%; zolpidem, 30.3%; OR, 1.41; 95% CI, 0.75-2.65). Second-stage therapy produced significant increases in responders for the 2 conditions, starting with BT (BT to zolpidem, 40.6% to 62.7%; OR, 2.46; 95% CI, 1.14-5.30; BT to CT, 50.1% to 68.2%; OR, 2.09; 95% CI, 1.01-4.35) but no significant change following zolpidem treatment. Significant increase in percentage of remitters was observed in 2 of 4 therapy sequences (BT to zolpidem, 38.1% to 55.9%; OR, 2.06; 95% CI, 1.04-4.11; zolpidem to trazodone, 31.4% to 49.4%; OR, 2.13; 95% CI, 0.91-5.00). Although response/remission rates were lower among patients with psychiatric comorbidity, treatment sequences that involved BT followed by CT or zolpidem followed by trazodone yielded better outcomes for patients with comorbid insomnia. Response and remission rates were well sustained through the 12-month follow-up.Behavioral therapy and zolpidem medication produced equivalent response and remission rates. Adding a second treatment produced an added value for those whose insomnia failed to remit with initial therapies.ClinicalTrials.gov Identifier: NCT01651442.
Abstract 15435: Pharmacogenomics-Based Prediction of Warfarin Maintenance Dose Overrides Racial Differences
Authors: Maki Sasano, Makiko Maeda, Masako Ohno, Yuya Fukuda, Shinichiro Maeda, Junya Yokoyama, Shigeru Miyagawa, Yoshiki Sawa, Yasushi Fujio
Journal: Circulation (2018)

Background: It is widely accepted that there is a large inter-individual difference in warfarin maintenance dose (WFD). Recent studies have demonstrated that inter-individual difference of WFD is l...
ヒト冠状微小動脈におけるアンジオテンシンII-アルドステロン相互作用にはGPR30,EGFR,および内皮一酸化窒素シンターゼが関与する | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: W Batenburg Wendy, M Jansen Pieter, J Van Den Bogaerdt Antoon, H J Danser Alexander
Journal: Cardiovascular Research (2012)
Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors
Authors: Stine E. Weis-Banke, Mads Lerdrup, Daniela Kleine-Kohlbrecher, Faizaan Mohammad, Simone Sidoli, Ole N. Jensen, Toshihiko Yanase, Tomoko Nakamura, Akira Iwase, Anthe Stylianou, Nadeem R. Abu-Rustum, Carol Aghajanian, Robert Soslow, Arnaud Da Cruz Paula, Richard P. Koche, Britta Weigelt, Jesper Christensen, Kristian Helin, Paul A.C. Cloos
Journal: Cancer Research (2020)

The mutant protein FOXL2C134W is expressed in at least 95% of adult-type ovarian granulosa cell tumors (AGCT) and is considered to be a driver of oncogenesis in this disease. However, the molecular mechanism by which FOXL2C134W contributes to tumorigenesis is not known. Here, we show that mutant FOXL2C134W acquires the ability to bind SMAD4, forming a FOXL2C134W/SMAD4/SMAD2/3 complex that binds a novel hybrid DNA motif AGHCAHAA, unique to the FOXL2C134W mutant. This binding induced an enhancer-like chromatin state, leading to transcription of nearby genes, many of which are characteristic of epithelial-to-mesenchymal transition. FOXL2C134W also bound hybrid loci in primary AGCT. Ablation of SMAD4 or SMAD2/3 resulted in strong reduction of FOXL2C134W binding at hybrid sites and decreased expression of associated genes. Accordingly, inhibition of TGFβ mitigated the transcriptional effect of FOXL2C134W. Our results provide mechanistic insight into AGCT pathogenesis, identifying FOXL2C134W and its interaction with SMAD4 as potential therapeutic targets to this condition. SIGNIFICANCE: FOXL2C134W hijacks SMAD4 and leads to the expression of genes involved in EMT, stemness, and oncogenesis in AGCT, making FOXL2C134W and the TGFβ pathway therapeutic targets in this condition. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/17/3466/F1.large.jpg.
Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation
Authors: Justin A. Edward, Ravi K. Gopal
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
P-19 Role of percutaneous radiofrequency ablation in unresectable, non-metastatic intrahepatic cholangiocarcinoma: A single-institution experience
Authors: A. Rizzo, A. Ricci, F. Dall'Olio, G. Frega, C. Felicani, G. Ercolani, S. Tavolari, M. Deserti, A. Palloni, S. De Lorenzo, F. Abbati, V. Mollica, I. Maggio, N. Tober, M. Pantaleo, M. Di Marco, F. Tovoli, M. Cescon, A. Pinna, A. Ardizzoni, C. Serra, G. Brandi
Journal: Annals of Oncology (2020)
Analysis of the contribution of MRP3 to in vivo chemosensitivity using knock out mice.
Authors: Martin G. Belinsky, Irina L. Shchaveleva, Zhe-Sheng Chen, Alan C. Sartorelli, Gary D. Kruh
Journal: Cancer Research (2004)

2456  Our laboratory and others have shown using cellular models that human multidrug resistance protein-3 (MRP3, ABCC3) is able to confer resistance to anti-cancer agents such as etoposide (1, 2). In order to gain insight into the contribution of MRP3 to in vivo drug sensitivity, mice homozygous for disruption of the mrp3 gene were generated and analyzed. Mrp3 (−/−) mice are grossly indistinguishable from their wild-type counterparts, have normal viability and fertility, show no obvious tissue abnormalities, and are indistinguishable from wild-type mice with respect to a wide range of serum chemical and hematological parameters. When tested for hypersensitivity to etoposide phosphate, we found no difference in mortality as compared to wild-type mice. To further examine the contribution of mrp3 to in vivo chemosensitivity, mrp3 knock out mice were intercrossed with triple knock out mice (mice deficient in mdr1a, mdr1b, and mrp1). Preliminary analysis of mrp3 function in this sensitive genetic background indicates that the absence of the mrp3 protein renders quadruple knock out mice hyper-sensitive to etoposide phosphate, suggesting that under certain circumstances the activity of mrp3 as an in vivo resistance factor can be observed. 1. Zeng, H., Bain, L. J., Belinsky, M. G., and Kruh, G. D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res, 59: 5964-5967, 1999. 2. Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., Scheper, R. J., Elferink, R. P., Baas, F., and Borst, P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A, 96: 6914-6919, 1999.
Telemedicine and Smart Working: Recommendations of the European Association of Urology
Authors: Moises Rodriguez Socarrás, Stacy Loeb, Jeremy Yuen-Chun Teoh, Maria J. Ribal, Jarka Bloemberg, James Catto, James N’Dow, Hendrik Van Poppel, Juan Gómez Rivas
Journal: European Urology (2020)
Abstract 128: Detection of Chest Compression Pauses by Automated External Defibrillators
Authors: Sofía Ruiz de Gauna, Jesus M Ruiz, Mikel Leturiondo, Purificación Saiz, Luis A Leturiondo, Iker Arana, Daniel Alonso, Karlos Ibarguren
Journal: Circulation (2018)

Introduction: Quality of cardiopulmonary resuscitation (CPR) improves if interruptions in chest compressions are minimized. Pauses in chest compressions can be deliberate (for rhythm ventilation or rhythm assessment) or inadvertent (rescuer distraction). Enhancing automated external defibrillators (AEDs) with the functionality of detecting chest compression pauses would be beneficial during resuscitation efforts and for debriefing purposes. Objective: To design and assess a method for the automated detection of chest compression pauses based on the transthoracic impedance (TI) signal acquired through AED defibrillation pads. Methods: Thirty-five AED recordings were randomly selected from a database collected by the Basque Country emergency medical service system (Spain). Recordings contained the ECG and the TI signals, and were randomly split into a training (10 episodes) and a test subset. Two experts on AED signal processing annotated the chest compression fraction (CCF) per episode, defined as the percent of total resuscitation time that compressions were performed. Our method computes the autocorrelation function (ACF) of the TI signal using consecutive 2-s segments. If the highest peak of the ACF in a predefined time interval is below a threshold, the 2-s segment is classified as a compression pause. The method was optimized using the training set. Results: Median (interquartile range, IQR) duration of the episodes in the test set was 1270 s (1113, 1605). CCF was 70.32% (66.12, 75.53). Sensitivity/positive predictive value in the detection of chest compression pauses were 97.64%/92.4%. The unsigned difference between annotated and computed CCF was 1.12% (0.43, 1.55). Conclusions: Computing the autocorrelation of the TI signal acquired through defibrillation pads could allow reliable detection of chest compression pauses. This method is simple and easy to implement in AEDs, and could be used to compute CCF for debriefing after resuscitation. Moreover, during real-time performance, AEDs could advise rescuers of inadvertent pauses or even proceed to rhythm analysis during ventilation pauses.
Social Prescribing — Transforming the Relationship between Physicians and Their Patients
Authors: Martin Roland, Sam Everington, Martin Marshall
Journal: New England Journal of Medicine (2020)

Interview with Dr. Martin Roland on opportunities for using socially oriented interventions when illnesses are influenced by social circumstances. (10:06)Download Many patients present to their physician with a problem that is not purely medical. Approaches that rely on social prescribing recognize that lifestyle changes could help alleviate many problems and that supportive resources are often available in a patient's community.